SNCA and neurodegenerative disease: The original patent was titled by “Proteolysis targeting chimeric (PROTAC) compound with E3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases” by Arvinas Operations, Inc. In this article, six key α-synuclein-targeting PROTACs were selected from the patent.